Drug combination for untreated chronic lymphocytic leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests two oral medications (sonrotoclax and zanubrutinib) for people newly diagnosed with CLL or SLL who need treatment. The goal is to see if this combination is effective and safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with CLL or SLL (types of blood cancer) and have not yet had any treatment for it.
- Your doctor has determined you need treatment now.
- You have swollen lymph nodes or other signs of disease that can be seen on a CT or MRI scan.
- Your blood counts, liver, and kidney function are adequate (doctor will confirm).
- You are generally in good health, able to be up and about (ECOG status 0-2), and expected to live more than 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different combinations of targeted drugs for people with CLL or SLL who have not had prior treatment for their disease. The goal is to see if these combinations are safe and effective.
This trial tests a three-drug combination for people who have not yet had treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to improve outcomes with a targeted, mostly oral regimen.
This trial tests whether adding a new drug, sonrotoclax, to the standard treatment zanubrutinib works better for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. It's for patients aged 65 and older who need therapy due to symptoms or blood cell issues.
This trial tests a new combination of drugs (sonrotoclax plus zanubrutinib) against another standard combination (venetoclax plus acalabrutinib) for people with chronic lymphocytic leukemia (CLL) who have not had treatment before. The goal is to see which combination works better.
This trial tests a combination of three drugs (sonrotoclax, rituximab, and zanubrutinib) for people with chronic lymphocytic leukemia, small lymphocytic lymphoma, or mantle cell lymphoma. The goal is to see if the combination works better than current treatments.
This trial tests a combination of two targeted drugs, zanubrutinib (a pill) and obinutuzumab (an infusion), for people with untreated CLL or SLL who need treatment. The goal is to see if this combination works well and is safe.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.